• Avacta will present new comparative analyses at its Science Day 2026 event, focusing on how its pre|CISION platform delivers a chemotherapy payload versus marketed antibody-drug conjugates.
• Results indicate faster, more selective tumor delivery for AVA6103 versus Enhertu or Datroway, supporting a potential differentiation case that is not dependent on a specific antibody target.
• Updated in vivo findings for AVA6207, first presented at AACR 2026, show deeper, more durable tumor responses in models where conventional chemotherapy or Enhertu showed tumor regrowth.
• Avacta plans to publish AVA6103 comparative findings at an upcoming academic meeting, followed by a peer-reviewed journal submission.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avacta Group plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605060200PRIMZONEFULLFEED9714121) on May 06, 2026, and is solely responsible for the information contained therein.